Thomson Reuters Names Texas Instruments as a Top 100 Global Innovator

Texas Instruments Incorporated (TI) today announced the company has been named a Thomson Reuters 2012 Top 100 Global Innovator. The program, an initiative of the IP Solutions business of Thomson Reuters, honors corporations and institutions around the world that are at the heart of innovation.

"Innovation fuels TI's success in developing the analog and embedded process technologies that are helping to shape the future of electronics," said Rich Templeton , chairman, president and chief executive officer of TI. "TI employees are passionate about innovation, and this recognition underscores our commitment to fostering it across every level of the company to enable game-changing, differentiated semiconductor solutions for TI customers."

The Thomson Reuters 2012 Top 100 Global Innovator methodology is based on four principle criteria: overall patent volume, patent grant success rate, global reach of the portfolio and patent influence as evidenced by citations. The peer-reviewed methodology was executed using a series of Thomson Reuters' proprietary patent-related metrics and tools including the Thomson Reuters Derwent World Patents Index® (DWPI). Comparative financial analysis was also completed. To view the full report, visit www.top100innovators.com

"Innovation is the foundation for economic prosperity and technological advancement," said David Brown , managing director, Thomson Reuters IP Solutions. "We congratulate the Thomson Reuters 2012 Top 100 Global Innovator companies and their leaders for recognizing the important role innovation plays in the successes of today and of tomorrow."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.